Please use this identifier to cite or link to this item:
10.1530/EJE-20-0204
Title: | Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules : A meta-analysis |
Authors: | Castellana, Marco Grani, Giorgio Radzina, Maija Guerra, Vito Giovanella, Luca Deandrea, Maurilio Ngu, Rose Durante, Cosimo Trimboli, Pierpaolo Department of Radiology |
Keywords: | 3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Endocrinology, Diabetes and Metabolism;Endocrinology;SDG 3 - Good Health and Well-being |
Issue Date: | Sep-2020 |
Citation: | Castellana , M , Grani , G , Radzina , M , Guerra , V , Giovanella , L , Deandrea , M , Ngu , R , Durante , C & Trimboli , P 2020 , ' Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules : A meta-analysis ' , European Journal of Endocrinology , vol. 183 , no. 3 , pp. 255-264 . https://doi.org/10.1530/EJE-20-0204 |
Abstract: | Objective: Several thyroid imaging reporting and data systems (TIRADS) ha ve been proposed to stratify the malignancy risk of thyroid nodule by ultrasound. The TIRADS by the Europea n Thyroid Association, namely EU-TIRADS, was the last one to be published. Design: We conducted a meta-analysis to assess the prevalence of malig nancy in each EU-TIRADS class and the performance of EU-TIRADS class 5 vs 2, 3 and 4 in detecting mal ignant lesions. Methods: Four databases were searched until December 2019. Original art icles reporting the performance of EU-TIRADS and adopting histology as reference standard were inc luded. The number of malignant nodules in each class and the number of nodules classified as true/false positiv e/negative were extracted. A random-effects model was used for pooling data. Results: Seven studies were included, evaluating 5672 thyroid nodules. The prevalence of malignancy in each EU-TIRADS class was 0.5% (95% CI: 0.0-1.3), 5.9% (95% CI: 2.6-9 .2), 21.4% (95% CI: 11.1-31.7), and 76.1% (95% CI: 63.7-88.5). Sensitivity, specificity, PPV, NPV, LR+, LR- A nd DOR of EU-TIRADS class 5 were 83.5% (95% CI: 74.5-89.8), 84.3% (95% CI: 66.2-93.7), 76.1% (95% CI: 63.7-88.5), 85.4% (95 % CI: 79.1-91.8), 4.9 (95% CI: 2.9-8.2), 0.2 (95% CI: 0.1-0.3), and 24.5 (95% CI: 11.7-51.0), respectively. A further improved performance was found after excluding two studies because of limited sample size and low prevalence of ma lignancy in class 5. Conclusions: A limited number of studies generally conducted using a retros pective design was found. Acknowledging this limitation, the performance of EU-TIRADS in stratifying th e risk of thyroid nodules was high. Also, EU-TIRADS class 5 showed moderate evidence of detecting malignant lesions. |
Description: | Publisher Copyright: © 2020 European Society of Endocrinology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved. |
DOI: | 10.1530/EJE-20-0204 |
ISSN: | 0804-4643 |
Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Performance_of_EU_TIRADS.pdf | 1.03 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.